Isis Moneer Mary Abraham Agreed to Be Excluded for 3 Years for Submitting Claims for Unused Portions of Injectable Drugs

On February 17, 2022, Isis Moneer “Mary” Abraham (Abraham), Roanoke, Virginia, agreed to be excluded under 42 U.S.C. 1320a-7(b)(7) for three years. Abraham was a co-owner and the office manager of Allergy and Asthma Associates, Inc. of Roanoke Virginia (AAA). As AAA’s office manager, Abraham was responsible for purchasing Xolair, a drug sold in single-use vials, and for billing and claims submission for the subcutaneous administration of Xolair to AAA’s patients. Abraham improperly retained and aggregated unused Xolair from prior subcutaneous administrations and then improperly submitted, or caused the submission of, false or fraudulent claims to the Medicare and Medicaid programs using Current Procedural Terminology code J2357 for the subcutaneous administration of the aggregated, unused Xolair to Medicare beneficiaries and Medicaid enrollees. OIG alleged that Abraham knew, or should have known, that the aggregated, unused Xolair from prior subcutaneous administrations should have been discarded instead of being subcutaneously administered to Medicare beneficiaries and Medicaid enrollees.

Share